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Research Highlights  
 C8-conjugates of pyrrolobenzodiazepines with benzofused rings modulate sequence-selective 
DNA binding 
 The conjugates bind best to guanines flanked by A/T-rich sequences. 
 Bi- and tri-phasic melting curves show that 14-mer oligonucleotides can bind more than one 
ligand 
 
ABSTRACT 
DNA footprinting and melting experiments have been used to examine the sequence-specific 
binding of C8-conjugates of pyrrolobenzodiazepines (PBDs) and benzofused rings including 
benzothiophene and benzofuran, which are attached using pyrrole- or imidazole-containing linkers.  
The conjugates modulate the covalent attachment points of the PBDs, so that they bind best to 
guanines flanked by A/T-rich sequences on either the 5'- or 3'- side. The linker affects the binding, 
and pyrrole produces larger changes than imidazole. Melting studies with 14-mer oligonucleotide 
duplexes confirm covalent attachment of the conjugates, which show a different selectivity to 
anthramycin and reveal that more than one ligand molecule can bind to each duplex.  
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1. Introduction 
Pyrrolobenzodiazepines [1] are sequence selective DNA minor groove binding ligands, of which 
anthramycin (1; Fig. 1) was the first compound to be isolated in the 1960s from cultures of 
Streptomyces [2]. These compounds have received considerable attention because of their potent 
antitumour activity, which results from covalent binding of the C11 position of the diazepine ring to 
the 2-amino group of a guanine [3, 4]. Naturally occurring PBDs such as anthramycin, tomaymycin, 
neothramycin and sibiromycin form adducts that span three base pairs, with guanine in the central 
position [5, 6], and their preferred binding site is 5'-AGA-3' [7], although more recent data suggest 
that they have a kinetic preference for 5′-YGR-3′ sequences [8] (R = purine, Y = pyrimidine). 
Synthetic PBD monomers with C2 (pyrrolidine ring)-aryl substitution exhibit nanomolar to picomolar 
cytotoxic potency against a number of tumour cell lines [9]. In an attempt to enhance their binding 
selectivity, bis-PBDs have been developed in which two PBD monomers are joined by a suitable 
linker and  SJG-136, which forms interstrand cross-links at 5'-RGATCY-3' as well as intrastrand 
cross-links and mono-adducts [10, 11], has reached Phase II clinical trial [12, 13]. Another 
approach for targeting longer DNA sequences is to prepare PBD C8-conjugates, in which 
heterocyclic rings such as pyrrole and imidazole are linked to the PBD anthranilate ring through 
amide bonds [14-17].  
Polyamides composed of pyrrole and imidazole heterocycles are able to form antiparallel 
dimers in the DNA minor groove and are widely known for their ability to recognize AT and TA 
base pairs with pyrrole-pyrrole pairs, and CG and GC with pyrrole-imidazole and imidazole-pyrrole 
pairs, respectively [18-20]. The conjugation of a PBD with a polyamide requires a suitable linker 
between these two entities. By comparing the binding energy of different linkers, a trimethylene 
group has been shown to provide a good isohelical fit in the DNA minor groove [15]. A conjugate of 
a PBD linked with a polyamide composed of two pyrroles was found to recognise the sequence 
(CCATT) in the promoter of DNA Topo IIα and to inhibit the binding of NF-γ, which is involved in 
cell cycle progression [17]. The combination of pyrrole and thiazole showed better DNA binding 
affinity than di-pyrroles [16], while addition of an imidazole offered superior sequence selectivity 
[14]. In addition, several other PBD conjugates have shown significant antibacterial [21] and 
antitubercular activity [22]. More recently, members of the PBD family have been developed as 
cytotoxic payloads for attachment to antibodies to form antibody-drug conjugates (ADCs) and a 
number of these are presently in the clinic for the treatment of various leukaemias and lung cancer 
[1]. 
There has been significant interest in trying to understand the molecular basis of the selectivity 
of known DNA-targeting agents with a view to designing novel molecules targeted to specific 
sequences within genes to allow selective modulation of expression for both research and 
therapeutic purposes.  We previously reported a series of C8-linked pyrrolobenzodiazepine (PBD)-
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poly(N-methylpyrrole) conjugates (e.g., GWL-78) which demonstrated the synergistic effect of 
joining a GC-specific PBD unit to an AT-recognizing polypyrrole fragments [15].  More recently we 
identified 4-(1-methyl-1H-pyrrol-3-yl)benzenamine (MPB) motif  as a GC-selective building block 
(Figure 1) and coupling MPB motif to PBDs through C8-position resulted in molecule with with sub-
nanomolar to femtomolar IC50 across 65 cell lines tested [23].  As part of our aim to develop 
pyrrolobenzodiazepine based selective antitumour compounds, and to understand the role of 
benzofused building blocks in sequence selectivity, we linked benzofuran, benzothiophene or 
benzopyrrole (indole) groups to the unsubstituted pyrrolobenzodiazepine core through a C4 linker. 
The benzofused groups were either directly linked to the PBD core through the C4 linker or 
separated by a further pyrrole/imidazole heterocycle to assess the impact of pyrrole/imidazole 
heterocycles on the DNA stabilisation potential of PBD-Benzofused conjugates.  
In this paper, we describe the DNA-binding properties of five C8-PBD-polyamide conjugates 
with benzofused rings (2-6; Fig. 1), and have examined their DNA binding sequence selectivity by 
DNase I footprinting and fluorescence melting. 
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2. Materials and methods  
2.1 C8-PBD-conjugates  
The structures of the C8-PBD-conjugates used in this work are shown in Fig. 1. Their synthesis 
will be reported elsewhere and the purity data are presented in the Supplementary material. The 
compounds were dissolved in dimethylsulfoxide at a concentration of 10 mM and stored at -20 °C. 
These were diluted to working concentrations in 10 mM Tris-HCl pH 7.5 containing 10 mM NaCl 
immediately before use. 
 
2.2 DNase I footprinting.  
Footprinting reactions were performed as previously described [24] using the DNA fragments 
HexA and HexB, which together contain all 64 symmetrical hexanucleotide sequences [25], and 
MS1 that contains all possible 134 tetranucleotide sequences [26]. The DNA fragments were 
obtained by cutting the parent plasmids with HindIII and SacI (for HexA and MS1) or EcoRI and 
PstI (for HexB), and were labelled at the 3'-end of the HindIII or EcoRI sites with [α-32P]dATP using 
reverse transcriptase or exo- Klenow fragment. After gel purification, the radiolabelled DNA was 
dissolved in 10 mM Tris-HCl pH 7.5 containing 0.1 mM EDTA, at a concentration of about 10 c.p.s 
per μL as determined on a hand held Geiger counter. 1.5 μL of radiolabelled DNA was mixed with 
1.5 μL ligand that had been freshly diluted in 10 mM Tris-HCl pH 7.5, containing 10 mM NaCl. The 
complexes were left to equilibrate for at least 12 hours before digesting with 2 μL DNase I (final 
concentration about 0.01 units/mL). The reactions were stopped after 1 minute by adding 4 μL of 
formamide containing 10 mM EDTA and bromophenol blue (0.1% w/v). The samples were then 
heated at 100 °C for 3 minutes before loading onto 8% denaturing polyacrylamide gels containing 
8 M urea. Gels were fixed in 10% acetic acid, transferred to 3MM paper, dried and exposed to a 
phosphor screen overnight, before analysing with a Typhoon phosphorimager. 
 
2.3 DNA thermal denaturation studies  
Fluorescence melting curves were determined using a Roche LightCycler in a total reaction 
volume of 20 μL as previously described [27]. For each reaction the final oligonucleotide 
concentration was 0.25 μM, diluted in 10 mM sodium phosphate pH 7.5 containing 100 mM NaCl, 
with ligand concentrations between 0.1 – 10 µM. The experiments used the duplexes shown in 
Table 1, in which one strand contained 5’-fluorescein (F), with a 3’-dabcyl quencher (Q) on the 
complementary strand. In a typical experiment the samples, which had been equilibrated overnight, 
were first denatured by heating to 95 °C at a rate of 0.1 °C.s-1. The samples were then maintained 
at 95 °C for 5 min before annealing by cooling to 30 °C at 0.1 °C.s-1. They were held at 25 °C for a 
further 5 min and then melted by heating to 95 °C at 0.1 °C.s-1. Recordings of the fluorescence 
emission at 520 nm were taken during both the melting steps as well as during annealing. The data 
were normalized to show the fractional change in fluorescence for each sample between the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 5 
starting and final values. Tm values were determined from the first derivatives of the melting profiles 
using the Roche LightCycler software. 
 
2.4 Molecular Modelling  
The ligand 2 was generated using ChemBioOffice and energy minimized using the 
MMFF94force-field [28]. The structure was then imported into AMBER (v11) [29] and the structure 
was manipulated using the AMBER modules antechamber and parmchk. Antechamber was used 
to convert the structure to mol2 format (through the application of Gasteiger charges) and missing 
parameters were generated using parmchk. The DNA sequence (5'-AAAAGTTAACTTTT-3') was 
then built using the AMBER module nuc and the parm99bsc0 [30] and gaff.dat force-fields were 
loaded. A further AMBER module xleap was used to align the ligand in the minor groove of DNA, 
with the N10 of the PBD either orientated within 2 Å of the exocyclic amine of the relevant guanine 
residue (in the case of non-covalent simulations) or N10-C11 covalently bound to DNA in the case 
of covalent simulations. The initial orientation was undertaken in the case of non-covalent 
simulations as PBDs are thought to form a reaction-mediating H-bond with DNA, which in turn pulls 
the molecule into the minor groove. 
Each adduct was then minimized in a stepwise manner to facilitate accommodation in the minor 
groove. In this procedure, positional restraints were initially used on the DNA atoms to keep their 
positions fixed, and the ligands were then energy minimized alone.  This was followed by full 
minimization of the system (without restraints) to ensure ligands were accommodated deep in the 
minor groove.  
Production simulations were undertaken in implicit solvent using the Generalised Born solvation 
method. This is equivalent to the Poisson Boltzmann method but includes a surface area term to 
enable accuracy in the simulation of macromolecules [23, 31].  A term to allow for monovalent 
electrostatic ion screening was also employed to simulate the effect of Na+ ions in the surrounding 
environment. The affinity of the ligand for DNA was then assessed using free energy of binding 
calculations; a detailed explanation of this established methodology can be found in our previous 
publications [23, 31]. 
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3. Results 
3.1 DNase I footprinting  
DNase I footprinting was used to identify the binding sites of the PBD-conjugates using the DNA 
fragments HexA and HexB, which together contain all 64 symmetrical hexanucleotide sequences 
[25] and MS1 that contains all 134 tetranucleotide sequences [26]. DNase I overestimates the size 
of ligand binding sites and produces footprints that are staggered towards the 3’-end of actual 
binding site. In the following description, for the sake of clarity, we refer to the central region of the 
sequence(s) that are protected in each of the footprints. The concentration dependence of the 
footprints for conjugates 2-6 with HexA and MS1 are shown in Fig. 2 and 3 and, for each DNA 
template, are compared with the cleavage pattern in the presence of anthramycin (1). Similar 
experiments with HexB are shown in Fig. S1. As expected, most of the footprints with anthramycin 
are located at the sequence RGR/YCY. For example, the two central footprints with HexA are in 
the sequences AGATCTAGAATTCCGGA and AGGCCT (RGR and YCY underlined). It is clear 
that the footprinting patterns with anthramycin are different to those produced by any of the 
conjugates, demonstrating that addition of the appending groups has affected the preferred binding 
sites. In general, the conjugates produce large footprints at higher concentrations (10 μM, 5μM and 
2 μM) which resolve into shorter regions of protection at lower concentrations. The footprinting 
patterns for 2, 3 and 4 are similar, while 5 and 6 appear to protect only a subset of these sites.  
With DNA fragment HexA (Fig. 2), 2, 3 and 4 produced four main footprints at low 
concentrations (1 μM). Each of these footprints occurs close to a block of AT residues, in 
sequences such as CGATATATATG, CAAATTTAG, GAATTC, GTTTAAAC and CTTAAG. If we 
assume that covalent attachment of the PBD moiety must occur at a guanine, then it appears that 
this can be located at either the 3’- or 5’- end of the footprint, with any arrangement of adjacent 
(A/T)n residues, where n is at least 4. The footprint at 5'-GAATTC has the reactive guanine at the 
5’-end of an AT-tract. A similar effect is seen at 5'-GTTTAAAC, with the guanine at the 5'-end of an 
AT-tract, though the footprint at 5'-CTTAAG would place the reactive G at the 3'-end of the AT-
tract. 5 binds to a greater number of sites at high concentrations (10 μM), generating large regions 
of protection, though there is little protection at lower ligand concentrations. 6 produces fewer 
footprints with the clearest footprint around GAATTC. 
Conjugates 2, 3 and 4 produced similar footprints with DNA fragment HexB (Fig. S1), with three 
or four sites persisting to 1 μM ligand concentration. These are again located close to AT-tracts 
and can be seen around CATATG, CTTATAAG, CAATTG and CTAATTAG. As for HexA, if we 
assume that the PBD moiety attaches to guanine, then this can be at either the 3'- or 5'-end of an 
AT-tract. No strong footprints are evident at guanines that are adjacent to only 2 AT base pairs, 
although since the HexA and HexB fragments were designed to contain symmetrical 
hexanucleotides, they do not contain any examples of only three consecutive AT pairs. 5 again 
generates long footprints at 10 μM, but produces fewer clear footprints at lower concentrations, 
which are strongest at CATATG, CAATTG and AATTAG. 6 also binds to only a subset of these 
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sites with clearest footprints around CTAATTA, AATTG and TAAGCGC and a weaker footprint at 
ATGCAT (Fig. S1). 
Similar DNase I footprinting patterns for the interaction of these compounds with MS1 are 
presented in Fig. 3. Once again 2, 3 and 4 generate similar footprints at three or four sites, which 
are clearest around GATTT, GTTAA, CTAT, ATAG, CAATTA, GTTATGTAAAG and GTTTTG. As 
noted for the other fragments, these all cluster around A/T tracts. The footprint around CTATC, 
which, although one of the weaker sites, is stronger for 2 and 3 than the other compounds, 
suggests that the AT-tract adjacent to the guanine only needs to be 3 base pairs long. 5 again 
produces very large footprints at the highest concentration (10 μM) with only a few sites around 
CAATTAG and CTATC that persist at 5 and 2 µM. As noted for the other fragments 6 produces 
fewer footprints, the strongest of which are around CAATTAG and AATGC. 
 
3.2 DNA melting studies  
The interaction of these PBD-conjugates with DNA was further evaluated by examining their 
effects on the melting temperature of a series of short 14-mer oligonucleotide duplexes. These 
duplexes contained a central GGTACC, GGATCC, GCTAGC, GCTTGC, GTATAC or GTTAAC 
embedded within an An.Tn tract in which the A-strand was labelled with 5’-fluorescein and the T-
strand with 3’-dabcyl (see Table 1). On duplex formation, the fluorescein and dabcyl are close 
together and the fluorescence is quenched. When the temperature is increased, the duplex melts 
and the fluorophore and quencher move apart and there is a large increase in the fluorescence. 
These studies were performed with ligand concentrations between 0.1-10 µM. Since the 
concentration of the duplex is only 0.25 µM there is an excess DNA over ligand at the lowest 
concentration.  
The effects of 1 μM of each ligand on the melting of the six oligonucleotides are shown in Fig. 
S2 and the data derived from these melting curves (and those with 10 µM ligand) are summarized 
in Table 2. The five conjugates (Fig. S2) each produced two elevated melting transitions; one 
around 65 °C and another above 85 °C.  Since the ligands are covalently bound to the DNA, rather 
than in dynamic equilibrium, the Tm values of each of these transitions did not change with ligand 
concentration. However, the relative proportions of the different transitions varied, such that a 
greater fraction of the melting curve appeared at higher temperatures with higher ligand 
concentrations. Each of the duplexes contains more than one guanine to which the conjugates 
could attach (i.e. two guanines for GTATAC and GTTAAC, and four each for GGTACC, GGATCC, 
GCTAGC and GCTTGC) and further transitions at higher temperatures were observed for most of 
the complexes as second (and third) PBDs attach to the oligonucleotides. The fraction of the 
melting transition that has shifted to the higher temperature therefore indicates the proportion of 
the duplex that has been modified within the incubation period, while the absolute values of the 
melting temperatures indicate the duplex stabilization that is imparted by the covalently bound 
ligands.  
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All five of these compounds clearly bind to each of these duplexes, though they have noticeably 
different relative effects.  At a concentration of 1 μM, 4 shifted the entire melting curve to higher 
temperatures with all six duplexes. A similar effect was produced by 1 µM 3, for which no 
transitions corresponding to the uncomplexed duplexes are evident, except for GGTACC and 
GCTAGC, which showed a small amount that had not reacted with the ligand. For most of the 
other ligand-duplex combinations a significant amount of the unmodified transition was still 
observed at 1 µM. 6 showed the weakest effect, with lower melting temperatures and a greater 
amount of uncomplexed duplex. All five conjugates had the greatest effect on the sequence with a 
central GGATCC, for which little or no unmodified duplex remained with 1 µM ligand. 5 produced 
smaller changes in melting temperature with GGTACC and GTTAAC than 2, 3 and 4, though it 
showed a strong interaction with GCTTGC, producing a single melting transition in the presence of 
1 µM with a ΔTm of 31 °C, the highest shift for any of the ligands with any of the duplexes. 
While there are subtle differences between these PBD-conjugates, their effects are very 
different from those of anthramycin itself. The concentration dependence of the melting curves of 
the six oligonucleotide duplexes in the presence of anthramycin are compared with those for 2 in 
Fig. 4. It can be seen that anthramycin produces much larger effects with GGTACC and GGATCC 
than the other oligonucleotide duplexes, and it had little or no effect on GTTAAC. In addition, with 
the exception of GGATCC, anthramycin only produced one elevated melting transition with ΔTm 
values that are smaller than with most of the conjugates (see Table 2), although similar to those 
seen with 6. GGTACC and GGATCC are the only oligonucleotides that contain the sequence 
RGR; GGTACC contains a single AGG site, while GGATCC contains AGGA (with two overlapping 
RGR sites) and TGGA on the two duplex strands. 
Although the PBDs form covalent links to their target guanines, these bonds are broken at high 
temperatures and the ligand dissociates from the DNA [32]. The fluorescence was therefore 
followed during the annealing curves as the samples were cooled back to 30 °C. The ligands only 
slowly re-attach to the DNA, and in each case, these annealing profiles were similar to those of the 
free uncomplexed DNA. After leaving at 30 °C for 5 minutes the samples were melted for a second 
time, recording the new melting transitions. Some of the ligands had reattached to the DNA during 
the annealing phase and so stabilised the duplexes relative to the drug-free controls. While the 
ΔTm values for this second melt were similar to those for when the complexes were first melted, the 
proportion of the profile showing an elevated melting temperature was always much lower than for 
the first melt. The results for these second melting experiments are shown in Table 3. Anthramycin 
had no effect when its complexes were melted for a second time and all these transitions were 
identical to those of the drug-free control. In general, the proportion of the transition corresponding 
to the free DNA in the presence of 1 µM of the conjugates was lowest for GGATCC, suggesting 
that they re-associated fastest with this sequence. In contrast to the first melt, all of the complexes 
produced only one elevated melting transition with 1 µM ligand, with no evidence of a second 
melting transition around 85 °C. However, this higher transition was seen with some of the ligands 
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at a concentration of 10 µM and was most pronounced for 4. 6 produced almost no changes in the 
melting temperature when the complexes were melted for the second time, with only a small effect 
for GCTAGC and GGATCC. No higher transitions were produced with 5 when the complexes were 
melted for the second time, and this ligand had no effect on both GTATAC and GTTAAC even at a 
concentration of 10 µM. However, 1 µM of 5 showed some of the greatest changes with GGTACC 
and GGATCC. 
 
3.3 Molecular Modelling  
Molecular modelling studies were undertaken on 2 in an effort to understand the interaction of 
the compound with DNA and to establish a rationale behind the biphasic curves observed in the 
FRET melting studies. The compound consists of a G-alkylating PBD coupled to a pyrrole-
benzofuran tail. The lack of hydrogen-bonding acceptors in the DNA-interactive face of ligand (i.e. 
within the pyrrole-benzofuran tail) suggests that the molecule should interact with AT tracts. 
Molecules of this type containing pyrrole chains have been previously shown to interact with 
inverted CCAAT boxes of DNA [14], and a similar interactivity pattern would be predicted for 2. As 
GTTAAC (containing an extended AT tract) would be expected to be an excellent substrate for 2 
was chosen for analysis 
In initial in silico positioning of 2 in the DNA minor groove suggests that  the molecule can span 5 
base pairs and, as the sequences used in the FRET experiments contain fourteen base pairs and 
more than one guanine, two ligands may be able to bind to the same duplex (i.e., dual-occupancy 
binding). Molecular dynamics simulations were undertaken on 2 in a variety of orientations in one 
sequence (GTTAAC) to ascertain whether dual occupancy was possible. Analysis of the extended 
sequence (AAAAGTTAACTTTT) suggests a number of potential configurations for the interaction 
of 2 with  GTTAAC. Firstly, a single ligand may be able to bind to G5 or G19 (with the A-ring 
oriented in the 5' or 3' direction) or two ligands might bind to either G5 (with the A-ring oriented 5') 
in combination with G19 (with the A-ring in a 3' orientation on the lower strand, see Fig. 5), or to G5 
(with the A-ring oriented 3') in combination with G19 (with the A-ring oriented 5’ on the lower 
strand).  
Free energy of binding calculations (Table 4) conducted on the four potential adducts in single 
occupancy form show that a 3’-orientation of the ligand’s A-ring is preferred over a 5’-orientation by 
~-2 kcal/mol. This is exemplified on visual analysis of these non-covalent simulations whereby an 
H-bond can be formed between the N10 proton of the PBD and the exocyclic amine of a guanine 
residue (i.e. G5). The H-bond is thought to facilitate nucleophilic attack of the guanine by pulling 
the PBD into the minor groove [23]. In contrast, this H-bond is not present in simulations of the 5' 
orientation of the A-ring of either G5 or G19 adducts, presumably due to inappropriate orientation 
of the N10 proton, and as a result is likely to be a less preferred adduct. 
Non-covalent simulations were conducted on the two possible dual-occupancy orientations of 2 
in the minor groove where the ligands do not overlap (i.e., concurrently covalently bound to G5 in 
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A-ring 5’ and G19 in A-ring 3’ or G5 in A-ring 3’ and G19 in A-ring 5’). Simulations suggest that 
either of these orientations is viable, and this hypothesis would explain the biphasic curves 
observed in the FRET studies. There is little difference between alkylation of G5 with the A-ring in 
5’ orientation and G19 with the A-ring in a 3’ orientationas the PBD will be bound to the sequence 
5’-GTTAAC-3’ in both instances, with alkylation of the top strand for G5 and the bottom strand for 
G19. The second adduct would then either be at 5’-AAAG-3’ (with the A-ring oriented 5’ to G5) or 
5’-TTTG-3’ (with the A-ring oriented 5’ to G19). The free energy of binding calculations undertaken 
suggest that these adducts are equally likely (Table 4).   
Furthermore, the potential of 2 to bind in an overlapping 2:1 (ligand:DNA) manner was also 
investigated.Simulations of 2 covalently bound to G5 and G19 in A-ring 3’ orientation (on the upper 
and lower strands respectively, see Fig. 5 lower panel) suggest that DNA interaction of this type is 
less favourable. Binding of two molecules of 2 in a 2:1 ratio (where an overlap in the same 
sequence is necessary) would require substantial widening of the minor groove as the exocyclic 
amines of the guanines are positioned towards the centre of the DNA, and once alkylated, a 
molecule of 2 would sterically prevent a second molecule binding. Furthermore, the van der Waals 
surface of the ligand is sufficient to occupy the full width of the DNA in 1:1 binding ratio, meaning a 
second binding event in this instance would be less favourable.   
 
 
4. Discussion 
PBDs are known to bind to the N2 position of guanine residues within the DNA minor groove 
and simple PBD monomers, such as anthramycin, are known to bind best to the sequence RGR, 
as confirmed by the footprinting and fluorescence melting experiments described here. When the 
PBD core is conjugated to other components through the C8 position, the sequence selectivity will 
be determined by the combined properties of the PBD, the linker and the side chain, though 
covalent attachment will still require the presence of a guanine residue. The profiles of the 
fluorescence melting curves confirm that these conjugates are indeed still covalently attached to 
the six oligonucleotides that we have studied, while the footprinting and melting experiments 
demonstrate that the conjugates have very different sequence binding properties to a simple PBD 
such as anthramycin, and the sequence RGR alone is no longer sufficient to define a good binding 
site. 
The footprinting data with the five PBD-conjugates show that the preferred sites all contain AT-
rich regions to the 5’- or 3’-side of the reactive guanine residues. Pyrrole and imidazole rings have 
been extensively studied as components of minor groove-binding ligands, in which imidazole is 
used to recognize GC base pairs in the 2:1 mode [33] although in the 1:1 mode it shows AT-
selectivity similar, but weaker to that of pyrrole [34, 35]. This is consistent with the observation that 
3 and 5 bind to similar sequences, though 5 displays a weaker interaction. 
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The fact that the C8-side chain affects the interaction suggests that this must bind first, before 
covalent attachment of the PBD. If the kinetics of binding were driven by the PBD, then the 
conjugates would have a similar selectivity to anthramycin and the initial covalent attachment 
would lock the complex onto its preferred RGR sites, irrespective of the flanking sequences.   
The presence of pyrrole or imidazole in the linker is important as compound 6, which lacks 
either of these rings, only binds to a few short sequences. Modelling studies suggest that 2 has an 
ideal shape for interactivity with the DNA minor groove, and the pyrrole unit is key in providing its 
isohelicity. As 2, 3, 4 and 5 all contain a five-membered heterocycle followed by a benzofused 
group, both their span and their ability to bind to DNA would be expected to be similar, and all 
compounds would be expected to form extensive van der Waals interactions with the DNA minor 
groove, thereby resulting in a similar sequence interactivity pattern.   The DNA melting results are 
in agreement with footprinting studies and modelling-based analysis. Compounds 2-6 form strong 
complexes and produce large changes in the melting curves of the 14-mer DNA duplexes, and 
molecular dynamics simulations show that the strong binding may be promoted by dual occupancy 
of the compounds in the DNA minor groove. The ΔTm values for the first melting transitions are 
significantly greater than anthramycin for all these conjugates (except 6), which again confirms the 
important role of the C8-side chains in promoting the interaction. 
The footprinting results suggest that the flanking A/T tract can be towards the 3'- or 5'-side of 
the guanine to which the PBD is attached. In contrast, previous structural studies have shown that 
the PBD phenyl ring (A ring) is oriented towards the 3’-end of the bound guanine [36, 37], from 
which we would predict that these conjugates should bind best to RG(A/T)n. In the melting 
experiments, all the putative central six base pair sites are flanked by An.Tn tracts. If the tail is 
oriented to the 3’-side of the guanine (i.e. towards the centre of the oligonucleotides), then we 
would expect GTATAC and GTTAAC to generate the best sites. If it is oriented in the opposite 
direction, then the conjugates should all have similar effects on the melting curves, as all the 
targets contain the sequence A4G on one strand (and T4G on the opposing complementary strand). 
For these melting experiments, the only sequences that contain the preferred RGR binding site are 
GGATCC, which has three such sites (AGGA, AGAA and TGAA (on the complementary strand)) 
and GGTACC, which contains only one such site (AGGT). As all the sequences are affected to 
some degree, the PBD portion of these ligands is clearly not restricted to interacting with RGR, 
though the sequence-dependent effects suggest that the central base pairs affect the binding 
affinity.   
The experiments in which the complexes were melted for a second time provide information on 
the kinetics of drug interaction. Only those PBD-oligonucleotide complexes with the fastest rates of 
covalent attachment will be affected in these second melts. In these experiments, sequences 
GGATCC and GGTACC show the lowest proportion of uncomplexed DNA, indicating faster rates 
of re-attachment, while GTTAAC and GATATC are the least affected. Under these conditions, 
there is no evidence for a second melting transition in the presence of 1 µM ligand. It is especially 
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noteworthy that, despite its weaker binding, 10 µM 5 produced clear monophasic melting curves 
with a single elevated melting transition, with all the oligonucleotides except GTATAC and 
GTTAAC. 6 did not affect the melting profiles in this second melt, which all resembled the ligand-
free transition, indicating that this molecule is slow to re-attach to its binding sites. A similar effect 
was seen with anthramycin, which also did not affect the second melting transitions. 
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Name Sequence 
GGTACC 
5’-F-AAAAGGTACCAAAA 
3’-Q-TTTTCCATGGTTTT 
GGATCC 
5’-F-AAAAGGATCCAAAA 
3’-Q-TTTTCCTAGGTTTT 
GCTAGC 
5’-F-AAAAGCTAGCAAAA 
3’-Q-TTTTCGATCGTTTT 
GCTTGC 
5’-F-AAAAGCTTGCAAAA 
3’-Q-TTTTCGTTCGTTTT 
GTTAAC 
5’-F-AAAAGTTAACAAAA 
3’-Q-TTTTCAATTGTTTT 
GTATAC 
5’-F-AAAAGTATACAAAA 
3’-Q-TTTTCATATGTTTT 
 
Table 1. Sequences of the fluorescently labelled oligonucleotides that were used for the 
fluorescence melting experiments. F = fluorescein, Q = dabcyl  
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  1 2 3 4 5 6 
GGTACC 
Tm = 41.4 °C 
ΔTm1 (ΔTm2)  20 28 (47) 29 (47) 28 (47) 24 (-) 22 (37) 
%free 70 (0) 20 (0) 10 (0) 0 (0) 20 (0) 50 (0) 
%T1 30 (100) 80 (50) 90 (50) 85 (25) 80 (100) 50 (45) 
%T2  0 (50)  0 (50) 15 (75) 0 (0) 0 (55) 
GTATAC 
Tm = 36.5 °C 
ΔTm1 (ΔTm2) 21 27 (48) 28 (50) 29 (50) 26 (47) 21 (38) 
%free 100 (80) 10 (0) 0 (0) 0 (0) 10 (0) 25 (0) 
%T1 0 (20) 45 (35) 50 (20) 45 (*) 75 (50) 50 (20) 
%T2  45 (65) 50 (80) 55 (*) 15 (50) 25 (80) 
GGATCC 
Tm = 42.3 °C 
ΔTm1 (ΔTm2) 18 (36) 29 (49) 29 (48) 30 (50) 30 (45) 22 (38) 
%free 20 (0) 0 (0) 0 (0) 0 (0) 10 (0) 10 (0) 
%T1 80 (75) 85 (40) 80 (20) 55 (25) 90 (55) 70 (35) 
%T2 0 (25) 15 (60) 20 (80) 45 (75) 0 (45) 20 (65) 
GTTAAC 
Tm = 37.8 °C 
ΔTm1 (ΔTm2)  26 (48) 26 (48) 27 (49) 24 (50) 20 (37) 
%free 100 15 (0) 0 (0) 0 (0) 25 (10) 45 (0) 
%T1 0 (0) 60 (40) 55 (20) 65 (30) 60 (60) 50 (20) 
%T2  25 (60) 45 (80) 35 (70) 15 (30) 5 (80) 
GCTAGC 
Tm = 43.9 °C 
ΔTm1 (ΔTm2) 22 29 (46) 29 (48) 29 (49) 28 (45) 23 (39) 
%free 100 (80) 0 (0) 5 (0) 0 (0) 30 (0) 15 (0) 
%T1 0 (20) 25 (35) 75 (35) 65 (40) 70 (55) 65 (40) 
%T2  75 (65) 20 (65) 35 (60) 0 (45) 20 (60) 
GCTTGC 
Tm = 44.6 °C 
ΔTm1 (ΔTm2) 20 29 (46) 29 (46) 29 (47) 31 (45) 23 (38) 
%free 100 (70) 0 (0) 0 (0) 0 (0) 0 (0) 20 (0) 
%T1 0 (30) 80 (40) 75 (40) 55 (40) 100 (70) 65 (35) 
%T2  20 (60) 25 (60) 45 (60) 0 (30) 15 (65) 
 
 
Table 2. Effects of 1 µM (and 10 µM) of the compounds on the fluorescence melting 
curves of the fluorescently labelled oligonucleotides. ΔTm1 and ΔTm2 correspond to the 
change in melting temperature of the first (and second) ligand-induced transition, relative 
to each uncomplexed oligonucleotide. Melting temperatures were reproducible to with less 
than 1 °C. %free, %T1, and %T2 correspond to the proportion of the transition that is 
represented by the uncomplexed DNA, first and second melting transitions respectively, 
with the values in the presence of 10 µM ligand in bracketsThese percentages are 
rounded to the nearest 5%. * indicates that the two transitions could not be clearly 
resolved. 
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  2 3 4 5 6 
GGTACC 
%free 100 (40) 95 (40) 85 (30) 45 (0) 100 (100) 
%T1 0 (60) 5 (60) 15 (60) 55 (100) 0 (0) 
%T2 0 (0) 0 (0) 0 (10) 0 (0) 0 (0) 
GTATAC 
%free 100 (55) 90 (55) 85 (35) 100 (95) 100 (100) 
%T1 0 (25) 10 (30) 15 ( 35) 0 (5) 0 (0) 
%T2 0 (20) 0 (15) 0 (30) 0 (0) 0 (0) 
GGATCC 
%free 80 (25) 75 (0) 45 (0) 50 (0) 100 (90) 
%T1 15 (75) 25 (90) 55 (70) 50 (100) 0 (10) 
%T2 0 (0) 0 (10) 0 (30) 0 (0) 0 (0) 
GTTAAC 
%free 100 (75) 100 (80) 80 (55) 100 (100) 100 (100) 
%T1 0 (25) 0 (20) 20 (45) 0 (0) 0 (0) 
%T2 0 (5) 0 (0) 0 (0) 0 (0) 0 (0) 
GCTAGC 
%free 80 (30) 80 (15) 70 (10) 85 (0) 100 (90) 
%T1 20 (55) 20 (60) 30 (50) 15 (100) 0 (10) 
%T2 0 (15) 0 (25) 0 (40) 0 (0) 0 (0) 
GCTTGC 
%free 90 (25) 85 (15) 60 (15) 70 (0) 100 (90) 
%T1 10 (65) 15 (65) 40 (60) 30 (100) 0 (10) 
%T2 0 (10) 0 (20) 0 (25) 0 (0) 0 (0) 
 
 
Table 3. Effects of 1 µM (and 10 µM) of the compounds on the fluorescence melting 
curves when the complexes were melted for the second time (i.e. after melting and 
annealing) . %free, %T1, and %T2 correspond to the proportion of the transition that is 
represented by the uncomplexed DNA, first and second melting transitions respectively. 
These percentages are rounded to the nearest 5%. 
 
 
 
 
DNA Base contact and orientation 
Free Energy of 
Binding (kcal/mol) 
G5 (A-ring 5’ orientation) -46.27 
G5 (A-ring 3’ orientation) -48.29 
G19 (A-ring 5’ orientation on the lower strand) -46.47 
G19 (A-ring 3’ orientation on the lower strand) -48.18 
    
Table 4. Free energy of binding calculations of 2 in various binding orientations in the 
sequence 5’-AAAAGTTAACTTTT-3’.Figures 
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Fig. 1. Structures of PBD-polyamide conjugates. (1 = anthramycin)  
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Fig. 2. DNase I footprinting of anthramycin (1) and conjugates 2-6 with the HexA DNA fragment. ‘Con’ shows DNase I cleavage in the absence of any 
added ligand and tracks labelled GA are Maxam-Gilbert markers specific for purines. The boxes indicate the locations of the main regions that are 
protected from DNase I cleavage, as determined by visual inspection of the gels; unfilled boxes show protection with 10 µM ligand while filled boxes 
show the location of footprints with low concentration (1 µM and lower). The right hand panel shows the sequence of the labelled DNA strand 
indicating the locations of the footprints produced by each of the conjugates. Filled boxes indicate the strongest footprints, while hatched boxes show 
the footprints that are observed with 10 µM ligand. 
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Fig. 3. DNase I footprinting of anthramycin (1) and conjugates 2-6 with the MS1 DNA fragment. ‘Con’ shows DNase I cleavage in the absence of any 
added ligand and tracks labelled GA are Maxam-Gilbert markers specific for purines. The boxes indicate the locations of the main regions that are 
protected from DNase I cleavage, as determined by visual inspection of the gels; unfilled boxes show protection with 10 µM ligand while filled boxes 
show the location of footprints with low concentration (1 µM and lower). The right hand panel shows the sequence of the labelled DNA strand 
indicating the locations of the footprints produced by each of the conjugates. Filled boxes indicate the strongest footprints, while hatched boxes show 
the footprints that are observed with 10 µM ligand. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 23 
 
 
 
Fig. 4. Fluorescence melting profiles for the six DNA duplexes in the presence of different 
concentrations of anthramycin (1) (upper panels) and 2 (lower panels). The identity of the 
central six bases is indicated above each panel. The target duplex concentration was 0.25 
µM.  
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Fig. 5. Low energy snapshot of molecular dynamics simulation of 2 (green) covalently bound to both G5 (magenta) and G19 (magenta) of the 
sequence 5'-AAAAGTTAACAAAA-3’. The G5 adduct is in A-ring 5’ orientation and binds to the sequence 5’-AAAG-3’ (where AT base pairs are 
shown as orange sticks) and the G19 adduct is in A-ring 3’ orientation on the sequence 5’-GTTAA-3’ (top panel schematic). The potential 
second, less favourable orientation of 2 shows the molecule bound in A-ring 3’ orientation alkylated to both G5 and G19, and positioned in the 
DNA in an overlapping 2:1 (ligand:DNA) manner.    
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C8-conjugates of pyrrolobenzodiazepines bind to guanines that are flanked by A/T-rich sequences 
on either the 5'- or 3'- side.  
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Research Highlights  
 C8-conjugates of pyrrolobenzodiazepines with benzofused rings modulate sequence-selective 
DNA binding 
 The conjugates bind best to guanines flanked by A/T-rich sequences. 
 Bi- and tri-phasic melting curves show that 14-mer oligonucleotides can bind more than one 
ligand 
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